 |
|
 |
|
 |
|
 |
|
|
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
Regenetech
Kyle Shanks, President
17045 El Camino Real
Suite 101
Houston, TX 77058
Office (281) 480-8899
Cell (832) 414-9520
Fax (281) 480-4998
Copyright
2011©
All Rights Reserved
MILESTONES
IN REGENETECH HISTORY
2002
April - The Company is founded under the name BioCell Innovations.
May -The Company acquires its original patent licensing rights through
a novation from NASA. (Note: Research on the Regenetech NASA licensed
bioreactor went as far back as shuttle STS-95 with John Glenn's work.)
May - Regenetech enters into a Sponsored Research Agreement with M.D.
Anderson Cancer Center in Houston, Texas.
August - Regenetech files its first patent
November - BioCell Innovations changes its name to Regenetech, Inc.
2003
January - Stage 1 research is fully completed; Regenetech
licenses its first intellectual property for treatment of Sickle Cell
Anemia.
April - Regenetech licenses an additional two (2) patents from NASA relating
to advanced bioreactor technology.
April - Regenetech enters into a Reimbursable Space Act Agreement with
NASA to continue development of adult stem cell expansion.
2005
January - Regenetech confirms its significantly expanded
adult stem cells were free from cancer risks and had no genetic mutations.
2005
- 2006
Regenetech expands its research at NASA and several universities
and completes the filing of its first 73 patent applications.
2007
August - Regenetech achieves 60 fold expansion of peripheral
blood adult stem cells.
2008
Regenetech enters into licensing agreement with Korea Stem
Cell Bank.
August - Regenetech enters into license with Cellgenia⃨ of Greece.
December - Regenetech enters into license with Magnafix. Dec 2008
2009
June - Regenetech achieves 100 fold expansion of peripheral
adult stem cells.
June -Regenetech enters into letter of intent with HCA.
2010
September-Regenetech moves their Offices from the Houston Medical Center
to the Nasa area near the Johnson Space Center (NASA).
September- Regenetech signs a license agreement with Regenavita for the
expansion of neo-natal cells in Latin America..
October-Regenetech signs a Joint Venture agreement with Health2O.
November-Regenetech enters into a new license agreement with NASA relating
to advanced Bio-molecule applications.
November-Regenetech signs a new non-exclusive license agreement with EHSI
for the expansion of human progenitor cells.
December-Regenetech completes the build-out of its new laboratory.
December-Regenetech forms a new company with Health20. The new company
is Zero G Cosmeceuticals.
December-Regenetech signs a Sponsored Research Agreement with Hyalose.
2011
Received issued botanical INCI designation
Received issued cellXpansion INCI designation
2012
Signed Joint Development Agreement with Arimed for Black Pitera cosmetic products in Southeast Asian countries
Signed Sales Agreement for Direct Response Marketing with Ignite Media
